Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients

Clinical and Translational Oncology

Volumn 17, Issue 7, 2015, Pages 539-546

  Kalinsky, K ^a,b   Mayer, J A ^c   Xu, X ^a   Pham, T ^c   Wong, K L ^c   Villarin, E ^c   Pircher, T J ^c   Brown, M ^a   Maurer, M A ^a,b   Bischoff, F Z ^c  

^a Department of Medicine College of Physicians and Surgeons Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Biocept Inc   (United States)

Author keywords

Breast cancer; Circulating tumor cell; Estrogen receptor; Microfluidic; Progesterone receptor

Indexed keywords

CYTOKERATIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIMARY TUMOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; ADULT; AGED; BONE TUMOR; BRAIN TUMOR; BREAST TUMOR; COHORT ANALYSIS; FEMALE; LIVER TUMOR; LUNG TUMOR; LYMPH NODE; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; SOFT TISSUE TUMOR; THORAX WALL; TUMOR CELL LINE; TUMOR EMBOLISM;

ADULT; AGED; BIOMARKERS, TUMOR; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODES; MCF-7 CELLS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOFT TISSUE NEOPLASMS; THORACIC WALL;

EID: 84937628043     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1275-1     Document Type: Article

References (23)

1. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JML. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 2011;17(11):3600–18. doi:10.1158/1078-0432.ccr-11-0255.
2. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009;9(Suppl 1):S6–17. doi:10.3816/CBC.2009.s.001 G44434VK149RM452.
3. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48.
4. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat. 2005;90(1):65–70. doi:10.1007/s10549-004-2756-z.
5. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009;20(12):1953–8. doi:10.1093/annonc/mdp263 mdp263.
6. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 2010;21(6):1254–61. doi:10.1093/annonc/mdp427 mdp427.
7. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol. 2009;20(9):1499–504. doi:10.1093/annonc/mdp028 mdp028.
8. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30(6):587–92. doi:10.1200/jco.2010.33.5232.
9. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–12. doi:10.1007/s10549-010-1163-x.
10. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol. 2009;27(31):5153–9. doi:10.1200/jco.2008.20.6664.
11. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14 Pt 1):4218–24. doi:10.1158/1078-0432.CCR-05-2821 12/14/4218.
12. Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011;122(2):356–60. doi:10.1016/j.ygyno.2011.04.039 S0090-8258(11)00340-4.
13. Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128(1):155–63. doi:10.1007/s10549-011-1508-0.
14. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9. doi:10.1038/nature06385 nature06385.
15. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007;253(2):180–204. doi:10.1016/j.canlet.2006.12.014 S0304-3835(06)00686-0.
16. Mayer JA, Pham T, Wong KL, Scoggin J, Sales EV, Clarin T, et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE platform. Cancer Genet. 2011;204(11):589–95. doi:10.1016/j.cancergen.2011.10.011 S2210-7762(11)00304-8.
17. Dickson MN, Tsinberg P, Tang Z, Bischoff FZ, Wilson T, Leonard EF. Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics. 2011;5:034119.
18. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, et al. A novel platform for detection of CK+ and CK − CTCs. Cancer Discov. 2011;1(7):580–6. doi:10.1158/2159-8290.CD-11-0215 2159-8290.CD-11-0215.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
20. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat. 2010;121(1):53–64. doi:10.1007/s10549-009-0460-8.
21. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11(4):R59. doi:10.1186/bcr2349 bcr2349.
22. Nadal R, Fernandez A, Sanchez-Rovira P, Salido M, Rodriguez M, Garcia-Puche JL, et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012;14(3):R71. doi:10.1186/bcr3180 bcr3180.
23. Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013;8(9):e75038. doi:10.1371/journal.pone.0075038.